Advertisement

Drugs

, Volume 74, Issue 12, pp 1411–1433 | Cite as

Fingolimod: A Review of Its Use in Relapsing-Remitting Multiple Sclerosis

  • Mark SanfordEmail author
Adis Drug Evaluation

Abstract

Fingolimod (Gilenya®) is an orally administered disease modifying agent (DMA) for use in relapsing-remitting multiple sclerosis (RRMS). In placebo-controlled trials in patients with RRMS with active disease, fingolimod 0.5 mg/day significantly reduced the annualized relapse rate (ARR) by approximately one-half over 2-year trial periods. It also significantly increased the proportion of patients with no disability progression, reduced deterioration from baseline in the Extended Disability Status Scale score and reduced MRI markers of disease progression (new/newly enlarging brain lesions and percentage change in brain volume). In a 12-month, comparison with intramuscular interferon β-1a (IFNβ- 1a) 30 μg/week, the ARR in fingolimod 0.5 mg/day recipients was significantly lower than in IFNβ-1a recipients by one-half; fingolimod recipients also had significantly lower MRI markers of disease progression. In extensions to the pivotal clinical trials, fingolimod exposure for up to 4 years was associated with low relapse rates and continuing benefits in terms of disability and disease progression. In clinical trials, adverse events in fingolimod recipients were generally mild to moderate in severity. In the pivotal placebo-controlled trial, serious adverse events occurred in similar proportions of fingolimod 0.5 mg/day and placebo recipients. First-dose bradycardia and atrioventricular block, which are generally asymptomatic, were clinically important adverse events associated with fingolimod in placebo-controlled trials. The risk for serious cardiovascular adverse events at the approved fingolimod dosage appears to be low in patients without pre-existing cardiac conditions. Fingolimod is an efficacious therapy for RRMS that reduces relapses, disability progression, new brain lesions and loss of brain volume. It has an acceptable tolerability profile and provides a useful alternative treatment in patients with RRMS who have responded poorly to other DMAs.

Keywords

Macular Oedema Progressive Multifocal Leukoencephalopathy Natalizumab Glatiramer Acetate Fingolimod 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Disclosure

The preparation of this review was not supported by any external funding. Mark Sanford is a salaried employee of Springer/Adis. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made by the author on the basis of scientific and editorial merit.

References

  1. 1.
    World Health Organization. Atlas: multiple sclerosis resources in the world. 2008. http://www.who.int/mental_health/neurology/Atlas_MS_WEB.pdf. Accessed 27 May 2014.
  2. 2.
    Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648):1502–17.PubMedCrossRefGoogle Scholar
  3. 3.
    Tremlett H, Zhao Y, Rieckmann P, et al. New perspectives in the natural history of multiple sclerosis. Neurology. 2010;74(24):2005–15.Google Scholar
  4. 4.
    Capkun-Niggli G, Nordstrom B, Lahoz R, et al. Mortality and morbidity in patients with multiple sclerosis compared with the general population: a retrospective analysis using the US Department of Defense database (abstract). 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis; 2–5 October 2013; Copenhagen.Google Scholar
  5. 5.
    Confavreux C, Vukusic S. Age at disability milestones in multiple sclerosis. Brain. 2006;129(3):595–605.PubMedCrossRefGoogle Scholar
  6. 6.
    Hohlfeld R, Barkhof F, Polman C. Future clinical challenges in multiple sclerosis: relevance to sphingosine 1-phosphate receptor modulator therapy. Neurology. 2011;76(8 Suppl 3):S28–37.PubMedCrossRefGoogle Scholar
  7. 7.
    Ali R, Nicholas RS-J, Muraro PA. Drugs in development for relapsing multiple sclerosis. Drugs. 2013;73(7):625–50.PubMedCrossRefGoogle Scholar
  8. 8.
    Gold R. Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved. CNS Drugs. 2011;25(1):37–52.PubMedCrossRefGoogle Scholar
  9. 9.
    European Medicines Agency. Gilenya 0.5 mg hard capsules; summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002202/WC500104528.pdf. Accessed 27 May 2014.
  10. 10.
    Novartis Pharmaceuticals Corporation. GILENYA (fingolimod) capsules (US prescribing information). 2012. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022527s008lbl.pdf. Accessed 27 May 2014.
  11. 11.
    European Medicines Agency. Gilenya (fingolimod): summary of opinion (post authorisation). 2014. http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion/human/002202/WC500165660.pdf. Accessed 28 May 2014.
  12. 12.
    Mehling M, Johnson TA, Antel J, et al. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis. Neurology. 2011;76(8 Suppl 3):S20–7.PubMedCrossRefGoogle Scholar
  13. 13.
    David OJ, Kovarik JM, Schmouder RL. Clinical pharmacokinetics of fingolimod. Clin Pharmacokinet. 2012;51(1):15–28.PubMedCrossRefGoogle Scholar
  14. 14.
    Scott LJ. Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis. CNS Drugs. 2011;25(8):673–98.PubMedCrossRefGoogle Scholar
  15. 15.
    Fyrst H, Saba JD. An update on sphingosine-1-phosphate and other sphingolipid mediators. Nat Chem Biol. 2010;6(7):489–97.PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Mehling M, Brinkmann V, Antel J, et al. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology. 2008;71(16):1261–7.PubMedCrossRefGoogle Scholar
  17. 17.
    Francis G, Kappos L, O’Connor P, et al. Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy. Mult Scler. 2014;20(4):471–80.PubMedCrossRefGoogle Scholar
  18. 18.
    Mehling M, Lindberg R, Raulf F, et al. Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis. Neurology. 2010;75(5):403–10.PubMedCrossRefGoogle Scholar
  19. 19.
    Mehling M, Hilbert P, Fritz S, et al. Antigen-specific adaptive immune responses in fingolimod-treated multiple sclerosis patients. Ann Neurol. 2011;69(2):408–13.PubMedCrossRefGoogle Scholar
  20. 20.
    Kowarik MC, Pellkofer HL, Cepok S, et al. Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS. Neurology. 2011;76(14):1214–21.PubMedCrossRefGoogle Scholar
  21. 21.
    Groves A, Kihara Y, Chun J. Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy. J Neurol Sci. 2013;328(1–2):9–18.PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Choi JW, Gardell SE, Herr DR, et al. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. Proc Natl Acad Sci US A. 2011;108(2):751–6.CrossRefGoogle Scholar
  23. 23.
    Van Doorn R, Van Horssen J, Verzijl D, et al. Sphingosine 1-phosphate receptor 1 and 3 are upregulated in multiple sclerosis lesions. Glia. 2010;58(12):1465–76.PubMedGoogle Scholar
  24. 24.
    Kovarik JM, Lu M, Riviere GJ, et al. The effect on heart rate of combining single-dose fingolimod with steady-state atenolol or diltiazem in healthy subjects. Eur J Clin Pharmacol. 2008;64(5):457–63.PubMedCrossRefGoogle Scholar
  25. 25.
    Kovarik JM, Slade A, Riviere GJ, et al. The ability of atropine to prevent and reverse the negative chronotropic effect of fingolimod in healthy subjects. Br J Clin Pharmacol. 2008;66(2):199–206.PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Boulton C, David OJ, Meiser K, et al. Tolerability and pulmonary effects during treatment initiation of once-daily fingolimod in subjects with moderate asthma. Clin Pharmacol Drug Devel. 2013;2(1):2–10.CrossRefGoogle Scholar
  27. 27.
    Nolan R, Gelfand JM, Green AJ. Fingolimod treatment in multiple sclerosis leads to increased macular volume. Neurology. 2013;80(2):139–44.PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Ocwieja M, Meiser K, David OJ, et al. Effect of fingolimod (FTY720) on cerebral blood flow, platelet function and macular thickness in healthy volunteers. Br J Clin Pharmacol. 2014. doi: 10.1111/bcp.12454.
  29. 29.
    Wu K, Mercier F, David OJ, et al. Population pharmacokinetics of fingolimod phosphate in healthy participants. J Clin Pharmacol. 2012;52(7):1054–68.PubMedCrossRefGoogle Scholar
  30. 30.
    Kovarik JM, Schmouder R, Barilla D, et al. Single-dose FTY720 pharmacokinetics, food effect, and pharmacological responses in healthy subjects. Br J Clin Pharmacol. 2004;57(5):586–91.PubMedCentralPubMedCrossRefGoogle Scholar
  31. 31.
    Kovarik JM, Slade A, Voss B, et al. Ethnic sensitivity study of fingolimod in white and Asian subjects. Int J Clin Pharmacol Ther. 2007;45(2):98–109.PubMedCrossRefGoogle Scholar
  32. 32.
    Kovarik JM, Schmouder RL, Serra D, et al. FTY720 pharmacokinetics in mild to moderate hepatic impairment. J Clin Pharmacol. 2005;45(4):446–52.PubMedCrossRefGoogle Scholar
  33. 33.
    Kovarik JM, Schmouder RL, Hartmann S, et al. Fingolimod (FTY720) in severe hepatic impairment: pharmacokinetics and relationship to markers of liver function. J Clin Pharmacol. 2006;46(2):149–56.PubMedCrossRefGoogle Scholar
  34. 34.
    David OJ, Ocwieja M, Meiser K, et al. Pharmacokinetics of fingolimod (FTY720) and a combined oral contraceptive coadministered in healthy women: drug-drug interaction study results. Int J Clin Pharmacol Ther. 2012;50(8):540–4.PubMedCrossRefGoogle Scholar
  35. 35.
    Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med. 2006;355(11):1124–40.PubMedCrossRefGoogle Scholar
  36. 36.
    Saida T, Kikuchi S, Itoyama Y, et al. A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis. Mult Scler. 2012;18(9):1269–77.PubMedCrossRefGoogle Scholar
  37. 37.
    Kappos L, Radue E-W, O’Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387–401.PubMedCrossRefGoogle Scholar
  38. 38.
    Calabresi PA, Radue E-W, Goodin D, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13(6):545–56.PubMedCrossRefGoogle Scholar
  39. 39.
    Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):402–15.PubMedCrossRefGoogle Scholar
  40. 40.
    O’Connor P, Polman C, Hohlfeld R, et al. Phase III FREEDOMS study extension: long-term safety of fingolimod (FTY720) in relapsing-remitting multiple sclerosis [abstract no. P 523]. 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis; 10–13 October 2012; Lyon.Google Scholar
  41. 41.
    Khatri B, Barkhof F, Comi G, et al. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol. 2011;10(6):520–9.PubMedCrossRefGoogle Scholar
  42. 42.
    Kappos L, Radue EW, O’Connor P, et al. Phase 3 FREEDOMS study extension: fingolimod (FTY720) efficacy in patients with relapsing-remitting multiple sclerosis receiving continuous or placebo- fingolimod switched therapy for up to 4 years [abstract no. P979, with poster]. 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis; 10–13 October 2012; Lyon.Google Scholar
  43. 43.
    Radue E-W, O’Connor P, Polman CH, et al. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Arch Neurol. 2012;69(10):1259–69.PubMedCrossRefGoogle Scholar
  44. 44.
    Devonshire V, Havrdova E, Radue EW, et al. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. [Erratum appears in Lancet Neurol. 2012;11(8):658]. Lancet Neurol. 2012;11(5):420–8.PubMedCrossRefGoogle Scholar
  45. 45.
    Kremenchutzky M, O’Connor P, Hohlfeld R, et al. Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study. Mult Scler Relat Dis. 2014;3:341–9.CrossRefGoogle Scholar
  46. 46.
    Bergval N, Sfikas N, Chin P, et al. Efficacy of fingolimod in pre-treated multiple sclerosis patients with disease activity: pooled analysis of FREEDOMS and FREEDOMS II [abstract no. P3.174]. 66th Annual Meeting of the American Association of Neurology; 26 April-3 May 2014; Philadelphia (PA).Google Scholar
  47. 47.
    Agius M, Meng X, Chin P, et al. Fingolimod therapy in early multiple sclerosis: an efficacy analysis of the TRANSFORMS and FREEDOMS studies by time since first symptom. CNS Neurosci Ther. 2014;20(5):446–51.PubMedCrossRefGoogle Scholar
  48. 48.
    Khatri B, Barkhof F, Comi G, et al. Fingolimod treatment increases the proportion of patients who are free from disease activity in multiple sclerosis compared to IFN-B1A: Results from a phase 3, active-controlled study (TRANSFORMS). 64th American Academy of Neurology Annual Meeting; 2012; New Orleans (LO).Google Scholar
  49. 49.
    Cohen JA, Barkhof F, Comi G, et al. Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. J Neurol. 2013;260(8):2023–32.PubMedCentralPubMedCrossRefGoogle Scholar
  50. 50.
    Khatri BO, Pelletier J, Kappos L. Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon beta-1a intramuscular: subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS). Mult Scler Relat Dis. 2014;3(3):355–63.CrossRefGoogle Scholar
  51. 51.
    Barkhof F, de Jong R, Sfikas N, et al. The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis. Mult Scler. 2014. doi: 10.1177/1352458514532317.PubMedCentralGoogle Scholar
  52. 52.
    Vollmer T, Jeffery D, Goodin D, et al. Long-term safety of fingolimod in patients with relapsing-remitting multiple sclerosis: results from phase 3 FREEDOMS II extension study [abstract no. P01.165]. Neurology. 2013;80(1).Google Scholar
  53. 53.
    Kappos L, Cohen J, Collins W, et al. Fingolimod in relapsing multiple sclerosis: an integrated analysis of safety findings. Mult Scler Relat Dis. 2014;3(6):494–504.CrossRefGoogle Scholar
  54. 54.
    Gold R, Comi G, Palace J, et al. Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study. J Neurol. 2014;261(2):267–76.PubMedCentralPubMedCrossRefGoogle Scholar
  55. 55.
    DiMarco JP, O’Connor P, Cohen JA, et al. First-dose effect of fingolimod: pooled safety data from three phase 3 studies. Mult Scler Rel Dis. 2014. doi: 10.1016/j.msard.2014.05.005.
  56. 56.
    Zarbin MA, Jampol LM, Jager RD, et al. Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis. Ophthalmology. 2013;120(7):1432–9.PubMedCrossRefGoogle Scholar
  57. 57.
    Francis G, Dahlke F, Von Rosenstiel P, et al. Assessment of potential risk of progressive multifocal leukoencephalopathy with fingolimod compared with that of natalizumab [abstract no. P01.160]. 65th Annual Meeting of the American Academy of Neurology; 16–23 March 2013; San Diego (CA).Google Scholar
  58. 58.
    US Food and Drug Administration. FDA drug safety communication: FDA investigating rare brain infection in patient taking Gilenya (fingolimod). http://www.fda.gov/Drugs/DrugSafety/ucm366529.htm. Accessed 27 May 2014.
  59. 59.
    European Medicines Agency. European Medicines Agency gives new advice to better manage risk of adverse effects on the heart with Gilenya [media release]. 10 May 2012. http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2012/04/WC500125690.pdf.
  60. 60.
    Ontaneda D, Hara-Cleaver C, Rudick RA, et al. Early tolerability and safety of fingolimod in clinical practice. J Neurol Sci. 2012;323(1–2):167–72.PubMedCentralPubMedCrossRefGoogle Scholar
  61. 61.
    Schurmann P, Basra S, Awar OG, et al. Abnormal rhythms in patients without known cardiac disease after a first dose of fingolimod. Mult Scler Relat Dis. 2014;3(3):408–12.CrossRefGoogle Scholar
  62. 62.
    US Food and Drug Administration. FDA Drug Safety Communication: revised recommendations for cardiovascular monitoring and use of multiple sclerosis drug Gilenya (fingolimod). 2012. http://www.fda.gov/drugs/drugsafety/ucm303192.htm. Accessed 27 May 2014.
  63. 63.
    McCormack PL. Natalizumab: a review of its use in the management of relapsing-remitting multiple sclerosis. Drugs. 2013;73(13):1463–81.PubMedCrossRefGoogle Scholar
  64. 64.
    Agashivala NV, Dastani HB, Carlton R, et al. Cost-effectiveness of fingolimod in treating patients with relapsing-remitting multiple sclerosis. Am J Pharm Benefits. 2011;3(6):320–8.Google Scholar
  65. 65.
    Lee S, Baxter DC, Limone B, et al. Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States. J Med Econ. 2012;15(6):1088–96.PubMedCrossRefGoogle Scholar
  66. 66.
    O’Day K, Meyer K, Miller RM, et al. Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis. J Med Econ. 2011;14(5):617–27.PubMedCrossRefGoogle Scholar
  67. 67.
    Bergvall N, Tambour M, Henriksson F, et al. Cost-minimization analysis of fingolimod compared with natalizumab for the treatment of relapsing-remitting multiple sclerosis in Sweden. J Med Econ. 2013;16(3):349–57.PubMedCrossRefGoogle Scholar
  68. 68.
    Heisen M, Treur MJ, van der Hel WS, et al. Fingolimod reduces direct medical costs compared to natalizumab in patients with relapsing-remitting multiple sclerosis in The Netherlands. J Med Econ. 2012;15(6):1149–58.PubMedCrossRefGoogle Scholar
  69. 69.
    Calabresi PA. Diagnosis and management of multiple sclerosis. Am Fam Physician. 2004;70(10):1935–44.PubMedGoogle Scholar
  70. 70.
    Association of British Neurologists. Revised (2009) Association of British Neurologists guidelines for prescribing in multiple sclerosis. http://theabn.org/abn/userfiles/file/ABN_MS_Guidelines_2009_Final(1).pdf. Accessed 27 May 2014.
  71. 71.
    Goodin DS, Frohman EM, Garmany GP Jr, et al. Disease modifying therapies for multiple sclerosis: report of the Therapeutics and Technology Assessment Committtee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology. 2002;58(2):169–78.PubMedCrossRefGoogle Scholar
  72. 72.
    National Institute for Clinical Excellence. Multiple sclerosis: management of multiple sclerosis in primary and secondary care. 2003. http://www.nice.org.uk/nicemedia/live/10930/29199/29199.pdf. Accessed 27 May 2014.
  73. 73.
    EMD Serono, Inc. Novantrone® (mitoxantrone for injection concentrate): US prescribing information. 2012. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019297s035lbl.pdf. Accessed 27 May 2014.
  74. 74.
    Biogen Idec, Inc. Tysabri® (natalizumab) injection for intravenous use: US prescribing information. 2014. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125104s813lbl.pdf. Accessed 27 May 2013.
  75. 75.
    Sprenger T, Kappos L. Alemtuzumab for multiple sclerosis: who to treat and what to treat? Lancet. 2012;380(9856):1795–7.PubMedCrossRefGoogle Scholar
  76. 76.
    European Medicines Agency. LEMTRADA 12 mg concentrate for solution for infusion: summary of product characteristics. 2014. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003718/WC500150521.pdf. Accessed 27 May 2013.
  77. 77.
    Genzyme. Genzyme’s LEMTRADA™ (alemtuzumab) application for MS accepted for review by the FDA [media release]. 28 January 2013. http://news.genzyme.com/press-release/genzymes_lemtrada-alemtuzumab-application-ms-accepted-review-fda.
  78. 78.
    Goodin DS, Cohen BA, O’Connor P, et al. Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review). Report of the Therapeutics and Technology Assessment Subcommitttee of the American Academy of Neurology. Neurology. 2008;71(9):766–73.PubMedCrossRefGoogle Scholar
  79. 79.
    Genzyme. Aubagio (teriflunomide) tablets for oral administration. 2012. http://products.sanofi.us/aubagio/aubagio.pdf. Accessed 27 May 2014.
  80. 80.
    Telfer NR, Colver GB, Morton CA. Guidelines for the management of basal cell carcinoma. Br J Dermatol. 2008;159(1):35–48.PubMedCrossRefGoogle Scholar
  81. 81.
    National Institute for Clinical Excellence. Fingolimod for the treatment of highly active relapsing-remitting multiple sclerosis. 2013. http://publications.nice.org.uk/. Accessed 27 May 2014.
  82. 82.
    Cascione M, Wynn D, Barbato LM, et al. Randomized, open-label study to evaluate patient-reported outcomes with fingolimod after changing from prior disease-modifying therapy for relapsing multiple sclerosis: EPOC study rationale and design. J Med Econ. 2013;16(7):859–65.PubMedCrossRefGoogle Scholar
  83. 83.
    Miller D, Cree B, Dalton C, et al. Study design and baseline characteristics of the INFORMS study: fingolimod in patients with primary multiple sclerosis. 65th American Academy of Neurology Annual Meeting; 2013; San Diego (CA).Google Scholar

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations